1. Home
  2. UAN vs TYRA Comparison

UAN vs TYRA Comparison

Compare UAN & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CVR Partners LP

UAN

CVR Partners LP

N/A

Current Price

$124.08

Market Cap

1.3B

Sector

Industrials

ML Signal

N/A

Logo Tyra Biosciences Inc.

TYRA

Tyra Biosciences Inc.

N/A

Current Price

$21.05

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UAN
TYRA
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Agricultural Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
2008
2021

Fundamental Metrics

Financial Performance
Metric
UAN
TYRA
Price
$124.08
$21.05
Analyst Decision
Strong Buy
Analyst Count
0
15
Target Price
N/A
★ $47.45
AVG Volume (30 Days)
15.0K
★ 1.2M
Earning Date
10-28-2026
11-04-2026
Dividend Yield
★ 8.52%
N/A
EPS Growth
★ 61.98
N/A
EPS
★ 12.06
N/A
Revenue
★ $606,038,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$10.34
★ N/A
Revenue Growth
★ 15.36
N/A
52 Week Low
$89.20
$12.98
52 Week High
$139.50
$40.65

Technical Indicators

Market Signals
Indicator
UAN
TYRA
Relative Strength Index (RSI) 40.90 41.02
Support Level $121.55 $18.66
Resistance Level $138.77 $27.00
Average True Range (ATR) 3.39 1.44
MACD -1.28 -0.15
Stochastic Oscillator 18.19 19.80

Price Performance

Historical Comparison
UAN
TYRA

About UAN CVR Partners LP

CVR Partners LP is a manufacturer and supplier of nitrogen fertilizer products. Its principal products include Urea Ammonium Nitrate (UAN) and ammonia. The company market ammonia products to industrial and agricultural customers and UAN products to agricultural customers. The primary geographic markets for its fertilizer products are Kansas, Missouri, Nebraska, Iowa, Illinois, Colorado, and Texas. The company's product sales are heavily weighted toward UAN.

About TYRA Tyra Biosciences Inc.

Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.

Share on Social Networks: